Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant P...

Full description

Saved in:
Bibliographic Details
Published in:Oncoscience 2015-03, Vol.2 (2), p.193-204
Main Authors: Arichi, Naoko, Mitsui, Yozo, Hiraki, Miho, Nakamura, Sigenobu, Hiraoka, Takeo, Sumura, Masahiro, Hirata, Hiroshi, Tanaka, Yuichiro, Dahiya, Rajvir, Yasumoto, Hiroaki, Shiina, Hiroaki
Format: Article
Language:English
Subjects:
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93
cites cdi_FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93
container_end_page 204
container_issue 2
container_start_page 193
container_title Oncoscience
container_volume 2
creator Arichi, Naoko
Mitsui, Yozo
Hiraki, Miho
Nakamura, Sigenobu
Hiraoka, Takeo
Sumura, Masahiro
Hirata, Hiroshi
Tanaka, Yuichiro
Dahiya, Rajvir
Yasumoto, Hiroaki
Shiina, Hiroaki
description In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p
doi_str_mv 10.18632/oncoscience.136
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4381710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1672605135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93</originalsourceid><addsrcrecordid>eNpVUU1LAzEQDaLYUnv3JDl62ZpsPnb3IkjxCwoiqNeQzU7byHazJlnRf2-wtdTTDMybN-_NQ-ickhktJcuvXGdcMBY6AzPK5BEa54zRjBesOD7oR2gawjshhPK8ZEKcolEuSlEJScbo-Q18sEZ32Aasce8idNHqFsc1eN3DEK3BUfsVRGw73DgDUX9Bm3kINkTdRdx7l5oIOLEY8GfoZKnbANNdnaDXu9uX-UO2eLp_nN8sMsOKQmaMVTVhOm9MUzUMmrxqiqqqkjNeyJI2PBeUCsLL2pQ1ryWXmieENDU3QtQVm6DrLW8_1BtoTNLtdat6bzfafyunrfo_6exardyn4qykBSWJ4HJH4N3HACGqjQ0G2lZ34IagqCxySQRlIkHJFmqS1-BhuT9DifoNQx2EoVIYaeXiUN5-4e_17AfUfonL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1672605135</pqid></control><display><type>article</type><title>Versican is a potential therapeutic target in docetaxel-resistant prostate cancer</title><source>PubMed Central</source><creator>Arichi, Naoko ; Mitsui, Yozo ; Hiraki, Miho ; Nakamura, Sigenobu ; Hiraoka, Takeo ; Sumura, Masahiro ; Hirata, Hiroshi ; Tanaka, Yuichiro ; Dahiya, Rajvir ; Yasumoto, Hiroaki ; Shiina, Hiroaki</creator><creatorcontrib>Arichi, Naoko ; Mitsui, Yozo ; Hiraki, Miho ; Nakamura, Sigenobu ; Hiraoka, Takeo ; Sumura, Masahiro ; Hirata, Hiroshi ; Tanaka, Yuichiro ; Dahiya, Rajvir ; Yasumoto, Hiroaki ; Shiina, Hiroaki</creatorcontrib><description>In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p&lt;0.05). Thus targeting versican is a potential therapeutic strategy in docetaxel-resistant prostate cancer.</description><identifier>ISSN: 2331-4737</identifier><identifier>EISSN: 2331-4737</identifier><identifier>DOI: 10.18632/oncoscience.136</identifier><identifier>PMID: 25859560</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Research Paper</subject><ispartof>Oncoscience, 2015-03, Vol.2 (2), p.193-204</ispartof><rights>Copyright: © 2015 Arichi et al. 2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93</citedby><cites>FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381710/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381710/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25859560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arichi, Naoko</creatorcontrib><creatorcontrib>Mitsui, Yozo</creatorcontrib><creatorcontrib>Hiraki, Miho</creatorcontrib><creatorcontrib>Nakamura, Sigenobu</creatorcontrib><creatorcontrib>Hiraoka, Takeo</creatorcontrib><creatorcontrib>Sumura, Masahiro</creatorcontrib><creatorcontrib>Hirata, Hiroshi</creatorcontrib><creatorcontrib>Tanaka, Yuichiro</creatorcontrib><creatorcontrib>Dahiya, Rajvir</creatorcontrib><creatorcontrib>Yasumoto, Hiroaki</creatorcontrib><creatorcontrib>Shiina, Hiroaki</creatorcontrib><title>Versican is a potential therapeutic target in docetaxel-resistant prostate cancer</title><title>Oncoscience</title><addtitle>Oncoscience</addtitle><description>In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p&lt;0.05). Thus targeting versican is a potential therapeutic strategy in docetaxel-resistant prostate cancer.</description><subject>Research Paper</subject><issn>2331-4737</issn><issn>2331-4737</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LAzEQDaLYUnv3JDl62ZpsPnb3IkjxCwoiqNeQzU7byHazJlnRf2-wtdTTDMybN-_NQ-ickhktJcuvXGdcMBY6AzPK5BEa54zRjBesOD7oR2gawjshhPK8ZEKcolEuSlEJScbo-Q18sEZ32Aasce8idNHqFsc1eN3DEK3BUfsVRGw73DgDUX9Bm3kINkTdRdx7l5oIOLEY8GfoZKnbANNdnaDXu9uX-UO2eLp_nN8sMsOKQmaMVTVhOm9MUzUMmrxqiqqqkjNeyJI2PBeUCsLL2pQ1ryWXmieENDU3QtQVm6DrLW8_1BtoTNLtdat6bzfafyunrfo_6exardyn4qykBSWJ4HJH4N3HACGqjQ0G2lZ34IagqCxySQRlIkHJFmqS1-BhuT9DifoNQx2EoVIYaeXiUN5-4e_17AfUfonL</recordid><startdate>20150302</startdate><enddate>20150302</enddate><creator>Arichi, Naoko</creator><creator>Mitsui, Yozo</creator><creator>Hiraki, Miho</creator><creator>Nakamura, Sigenobu</creator><creator>Hiraoka, Takeo</creator><creator>Sumura, Masahiro</creator><creator>Hirata, Hiroshi</creator><creator>Tanaka, Yuichiro</creator><creator>Dahiya, Rajvir</creator><creator>Yasumoto, Hiroaki</creator><creator>Shiina, Hiroaki</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150302</creationdate><title>Versican is a potential therapeutic target in docetaxel-resistant prostate cancer</title><author>Arichi, Naoko ; Mitsui, Yozo ; Hiraki, Miho ; Nakamura, Sigenobu ; Hiraoka, Takeo ; Sumura, Masahiro ; Hirata, Hiroshi ; Tanaka, Yuichiro ; Dahiya, Rajvir ; Yasumoto, Hiroaki ; Shiina, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Arichi, Naoko</creatorcontrib><creatorcontrib>Mitsui, Yozo</creatorcontrib><creatorcontrib>Hiraki, Miho</creatorcontrib><creatorcontrib>Nakamura, Sigenobu</creatorcontrib><creatorcontrib>Hiraoka, Takeo</creatorcontrib><creatorcontrib>Sumura, Masahiro</creatorcontrib><creatorcontrib>Hirata, Hiroshi</creatorcontrib><creatorcontrib>Tanaka, Yuichiro</creatorcontrib><creatorcontrib>Dahiya, Rajvir</creatorcontrib><creatorcontrib>Yasumoto, Hiroaki</creatorcontrib><creatorcontrib>Shiina, Hiroaki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncoscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arichi, Naoko</au><au>Mitsui, Yozo</au><au>Hiraki, Miho</au><au>Nakamura, Sigenobu</au><au>Hiraoka, Takeo</au><au>Sumura, Masahiro</au><au>Hirata, Hiroshi</au><au>Tanaka, Yuichiro</au><au>Dahiya, Rajvir</au><au>Yasumoto, Hiroaki</au><au>Shiina, Hiroaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Versican is a potential therapeutic target in docetaxel-resistant prostate cancer</atitle><jtitle>Oncoscience</jtitle><addtitle>Oncoscience</addtitle><date>2015-03-02</date><risdate>2015</risdate><volume>2</volume><issue>2</issue><spage>193</spage><epage>204</epage><pages>193-204</pages><issn>2331-4737</issn><eissn>2331-4737</eissn><abstract>In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p&lt;0.05). Thus targeting versican is a potential therapeutic strategy in docetaxel-resistant prostate cancer.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>25859560</pmid><doi>10.18632/oncoscience.136</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2331-4737
ispartof Oncoscience, 2015-03, Vol.2 (2), p.193-204
issn 2331-4737
2331-4737
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4381710
source PubMed Central
subjects Research Paper
title Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A55%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Versican%20is%20a%20potential%20therapeutic%20target%20in%20docetaxel-resistant%20prostate%20cancer&rft.jtitle=Oncoscience&rft.au=Arichi,%20Naoko&rft.date=2015-03-02&rft.volume=2&rft.issue=2&rft.spage=193&rft.epage=204&rft.pages=193-204&rft.issn=2331-4737&rft.eissn=2331-4737&rft_id=info:doi/10.18632/oncoscience.136&rft_dat=%3Cproquest_pubme%3E1672605135%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3776-339b03a2dcd9d3ed29d799918647681d425115048bc8b4b646a4d796cb4c55b93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1672605135&rft_id=info:pmid/25859560&rfr_iscdi=true